Which SSRI is associated with the least risk for pregnant and breastfeeding women?

Sertraline is recognized for having a comparatively favorable safety profile in pregnant and breastfeeding women among the SSRIs. Research indicates that sertraline has less association with congenital malformations when used in pregnancy, as well as lower risks of complications such as neonatal withdrawal syndrome and persistent pulmonary hypertension of the newborn compared to some other antidepressants.

Additionally, sertraline is known to have a relatively lower level of transfer into breast milk, which makes it a preferred choice for breastfeeding mothers. This characteristic ensures that while the mother receives essential treatment for her mental health conditions, the infant is exposed to the lowest possible concentrations of the medication.

This dual safety aspect enhances sertraline's standing as a suitable option for women during pregnancy and breastfeeding, thereby supporting maternal health while minimizing potential risks to the fetus or nursing child.